|
Long-term efficacy of Gilenya® reinforced by new 'no evidence of disease activity' (NEDA-4) analysis in MS patients over seven years
|
08 October 2015 |
|
Novartis launches 'Novartis Access', a portfolio of affordable medicines to treat chronic diseases in lower-income countries
|
28 September 2015 |
|
Patients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar® + Mekinist®
|
28 September 2015 |
|
Novartis receives EU approval for Farydak®, the first in its class of anticancer agents approved for patients with multiple myeloma
|
04 September 2015 |
|
Novartis announces global partnership with Amgen to develop and commercialize pioneering neuroscience treatments
|
02 September 2015 |
|
Novartis acquires all remaining rights to GSK's Ofatumumab to develop treatments for MS and other autoimmune indications
|
21 August 2015 |
|
Novartis malaria treatment Coartem® 80/480mg receives WHO prequalification, enabling greater access for patients
|
17 July 2015 |
|
Novartis Pharmaceuticals launches the first app for visually impaired people for use with the Apple Watch and other smart watches
|
30 June 2015 |
|
Novartis deepens its industry leading pipeline with acquisition of Spinifex Pharmaceuticals, Inc.
|
29 June 2015 |
|
Novartis highlights strong innovation momentum at its second Meet Novartis Management investor day
|
18 June 2015 |